IMNN|EPS -$6.83|Net Loss $14.5MIMUNON is a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies. The company’s lead clinical program, IMNN-001, is currently advancing through a pivotal Phase 3 trial for the localized treatment of newly diagnosed advanced ovarian cancer.
For the year ended December 31, 2025, IMUNON recorded $0 in revenue. The company’s earnings per share (EPS) was a net loss of $6.83 per basic and diluted share. The total net loss for the full year amounted to $14.5 million.
Total operating expenses for 2025 were $14.7 million, representing a 23% decrease compared to 2024. This reduction was primarily due to lower research, development, and administrative costs. As of December 31, 2025, IMUNON maintained a balance of $8.8 million in cash and cash equivalents.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.